Dyadic International Inc.

DYAI

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001213809

E

weakest fifth of 370 graded peers in healthcare

rank 336 of 370; percentile 90.8; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	D percentile 65.3
Solvency	D/E percentile 78.2
Growth and financing	D percentile 66.1
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $9.9M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, distress not computable: fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Apr 30, 2026 182 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$0.40 2026-10-28; market equity $14.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 25, 2026

competitors for such products have more capital resources, larger R&D and marketing staff, facilities and capabilities, and greater experience in research and development, regulatory approval, manufacturing and commercialization of technology and products. Accordingly, our competitors may be able to develop technologies and products more rapidly. Our future success will depend on our ability to maintain a competitive position with respect to technological advances in terms of product and process quality, stability, safety, productivity and cost.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 65.3						
Gross profitability	7.7%	32.3%		79.3	369	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(16.7%)	(6.6%)	26.1	805	2025-12-31
Gross margin stability, five years	16.5 pts	2.8 pts	90.5	242	2025-12-31
Solvency, sleeve percentile 78.2					
Twelve-month failure probability	2.77%	0.07%	93.1	246	2026-06-30
Altman Z double-prime	(31.25)	(0.33)	81.2	751	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	2.68x	2.94x	60.3	832	2025-12-31
Growth and financing, sleeve percentile 66.1					
Revenue growth, three-year compound	1.8%	10.1%	67.5	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(10.2%)	2.1%	69.8	697	2025-12-31
Net share issuance, one year	21.1%	2.5%	61.1	633	2026-03-24

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 2.3 months
Distress	CHS probability 2.774093%; universe top-decile threshold 0.977859%

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
331	Brookdale Senior Living Inc. (BKD)	89.4	E	
332	Lifeward Ltd. (LFWD)	89.7	E	dilution, late filer
333	Canopy Growth Corp. (CGC)	90.0	E	dilution, fortress balance sheet
334	Aytu Biopharma, Inc. (AYTU)	90.2	E	fortress balance sheet
335	Q32 Bio Inc. (QTTB)	90.5	E	
336	Dyadic International Inc. (DYAI)	90.8	E	short runway, distress
337	Editas Medicine, Inc. (EDIT)	91.1	E	fortress balance sheet
338	Century Therapeutics, Inc. (IPSC)	91.3	E	dilution, fortress balance sheet
339	Beyond Air, Inc. (XAIR)	91.6	E	dilution, short runway, distress
340	Precision Biosciences Inc. (DTIL)	91.9	E	dilution, fortress balance sheet
341	Airsculpt Technologies, Inc. (AIRS)	92.1	E	late filer

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-28 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(53.0%)	7.7%	12
Distance from 52-week high	(73.2%)	(27.7%)	11
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	(0.17)	0.27	6
Sales to price	0.22	0.31	41
Composite equity issuance, five years	27.9%	20.5%	55
Relative strength against the sector, log excess return	(0.97)	(0.14)	12

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$1.4M
Operating cash flow, four quarters	-$7.4M
Months of runway	2.3
Days since last periodic filing	78 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$65,135

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.1M	2025-12-31	2026-03-25	10-K	26-012672
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.3M	2025-12-31	2026-03-25	10-K	26-012672
3	assets	us-gaap:Assets	$9.9M	2025-12-31	2026-03-25	10-K	26-012672
4	net income	us-gaap:NetIncomeLoss	-$7.4M	2025-12-31	2026-03-25	10-K	26-012672
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.7M	2025-12-31	2026-03-25	10-K	26-012672
6	assets	us-gaap:Assets	$9.9M	2024-12-31	2026-03-25	10-K	26-012672
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.5M	2024-12-31	2026-03-25	10-K	26-012672
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$1.2M	2024-12-31	2026-03-25	10-K	26-012672
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.9M	2023-12-31	2025-03-26	10-K	25-009350
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.0M	2023-12-31	2025-03-26	10-K	25-009350
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.9M	2022-12-31	2024-03-28	10-K	24-009857
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.1M	2022-12-31	2024-03-28	10-K	24-009857
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.4M	2021-12-31	2023-03-29	10-K	23-008425
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$1.9M	2021-12-31	2023-03-29	10-K	23-008425
15	current assets	us-gaap:AssetsCurrent	$9.9M	2025-12-31	2026-03-25	10-K	26-012672
16	current liabilities	us-gaap:LiabilitiesCurrent	$3.7M	2025-12-31	2026-03-25	10-K	26-012672
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$93.5M	2025-12-31	2026-03-25	10-K	26-012672
18	operating income	us-gaap:OperatingIncomeLoss	-$7.2M	2025-12-31	2026-03-25	10-K	26-012672

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	book equity	us-gaap:StockholdersEquity	$1.2M	2025-12-31	2026-03-25	10-K	26-012672
20	liabilities	us-gaap:Liabilities	$8.7M	2025-12-31	2026-03-25	10-K	26-012672
21	assets	us-gaap:Assets	$8.2M	2023-12-31	2025-03-26	10-K	25-009350
22	assets	us-gaap:Assets	$13.7M	2022-12-31	2024-03-28	10-K	24-009857
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	36,438,703	2026-03-24	2026-04-30	10-K/A	26-020402
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	30,090,661	2025-03-26	2025-03-26	10-K	25-009350

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.